Beraprost (sodium)

496807-11-5

420.47

DMSO : 250 mg/mL (594.57 mM; Need ultrasonic)

GPCR/G Protein

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation^[1]. IC50 & Target: prodrug of PGI2; Vasodilator^[1] In Vitro: Beraprost sodium (0.1, 1.0, and 10.0 uM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity^[1]. Beraprost sodium (0.1, 1.0, and 10.0 uM; 24 hours) treatment let VE-cadherin at regions of cell-cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions^[1].
In Vivo: Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis^[1].